Compare Novartis AG (NVS) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Invesco NASDAQ 100 ETF — how do they compare? Novartis AG trades at $139.98 (market cap $262.28B), while Invesco NASDAQ 100 ETF trades at $293.88. The key difference: Novartis AG pays a 3.45% dividend while Invesco NASDAQ 100 ETF pays none, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | QQQM | |
|---|---|---|
Market Cap | $262.28B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $307.23 |
52-Week Low | $121.80 | $229.87 |
Enterprise Value | $303.60B | — |
Dividend Yield | 3.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
QQQM trades at $295.76, down 0.1% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks the Nasdaq-100 index, offering growth exposure with a low expense ratio. Recent news highlights its role in diversified portfolios and comparisons with similar funds like QQQ, emphasizing cost efficiency for long-term investors.
The outlook remains positive due to strong growth stock representation, though risks include market volatility and concentration in tech. Analysts view it as a core holding for growth exposure, with technical support near $295 suggesting near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
